Comparative effectiveness and innovation

Toby Cosgrove, CEO of the Cleveland Clinic, worries that comparative effectiveness research will stifle medical innovation. I don’t think that’s likely.

I’m quoted in the Cleveland Plain Dealer today disagreeing with Cosgrove. Here’s what I said:

David E. Williams, a health-care business consultant and principal at MedPharma Partners in Boston, doesn’t see comparative effectiveness slowing innovation either.

“I think there are always concerns about whether payment policies are going to retard medical innovation,” Williams said. “But in practice, there’s been a strong willingness on the part of government and private payers to pay for new treatments.”

We should embrace comparative-effectiveness research, Williams said.

“It will make it more likely that things that are truly innovative will make it to market and it will discourage things that are flashy and expensive but don’t add much clinical value,” he said.

August 19, 2010

One thought on “Comparative effectiveness and innovation”

  1. Although there may appear some drawbacks such as possible cost and expenses, comparative effectiveness poses an approach that would surely benefit the public. Evaluating the current health trends including the therapies and the innovation would determine hitches and solutions for improvement.

Leave a Reply

Your email address will not be published. Required fields are marked *